NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 305 filers reported holding NOVOCURE LTD in Q3 2022. The put-call ratio across all filers is 1.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,585,559 | +260.5% | 98,177 | +826.4% | 0.11% | +269.0% |
| Q2 2023 | $439,817 | -14.9% | 10,598 | +50.3% | 0.03% | -21.6% |
| Q4 2022 | $517,117 | +149.8% | 7,050 | +158.5% | 0.04% | +131.2% |
| Q3 2022 | $207,000 | -83.3% | 2,727 | -84.7% | 0.02% | -86.0% |
| Q2 2022 | $1,241,000 | -40.1% | 17,858 | +0.1% | 0.11% | -25.0% |
| Q3 2021 | $2,072,000 | +1557.6% | 17,841 | +1782.0% | 0.15% | +1166.7% |
| Q1 2021 | $125,000 | -72.0% | 948 | -87.4% | 0.01% | -79.7% |
| Q2 2020 | $446,000 | -33.1% | 7,523 | -5.0% | 0.06% | -10.6% |
| Q4 2019 | $667,000 | +813.7% | 7,921 | +580.5% | 0.07% | +842.9% |
| Q2 2019 | $73,000 | -85.3% | 1,164 | -88.7% | 0.01% | -85.1% |
| Q1 2019 | $495,000 | +173.5% | 10,281 | +14.4% | 0.05% | +176.5% |
| Q4 2017 | $181,000 | +110.5% | 8,989 | +80.5% | 0.02% | +112.5% |
| Q2 2017 | $86,000 | – | 4,980 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |